Kairos Pharma shares are trading lower. The company announced a collaboration with Bayer to evaluate ENV-105 with XOFIGO in metastatic castration-resistant prostate cancer involving bone.

Benzinga Newsdesk www.benzinga.com Positive 76.8%

Neg 0% Neu 0% Pos 76.8%

Comments

No comments yet. Be the first!